BeOne Medicines (ONC) Equity Average (2016 - 2026)
BeOne Medicines (ONC) reported Equity Average of $4.6 billion for Q1 2026, up 33.52% year-over-year from $3.4 billion in Q1 2025, and up 7.43% on a QoQ basis from $4.2 billion in Q4 2025.
BeOne Medicines (ONC) has 11 years of Equity Average data on file, last reported at $4.6 billion in Q1 2026.
- Quarterly Equity Average rose 33.52% year-over-year to $4.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 33.52% YoY) and the FY2025 annual result came in at $3.8 billion, up 11.99% from the prior year.
- Equity Average climbed to $4.6 billion in Q1 2026 per ONC's latest filing, from $4.2 billion in the prior quarter.
- Across five years, Equity Average topped out at $6.0 billion in Q1 2022 and bottomed at $3.4 billion in Q2 2024.
- The 5-year median for Equity Average is $3.9 billion (2025), against an average of $4.1 billion.
- The widest annual swing landed in 2022, when Equity Average soared 51.24%; it then retreated 28.27% in 2023.
- Tracing ONC's Equity Average over 5 years: stood at $4.5 billion in 2022, then dropped by 19.23% to $3.7 billion in 2023, then dropped by 7.29% to $3.4 billion in 2024, then gained by 25.45% to $4.2 billion in 2025, then rose by 7.43% to $4.6 billion in 2026.
- Per Business Quant, the three latest ONC Equity Average figures stand at $4.6 billion (Q1 2026), $4.2 billion (Q4 2025), and $3.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 31.34 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 932.28 Mn |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 4.56 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.56 Bn |
| Dec 31, 2025 | 4.25 Bn |
| Sep 30, 2025 | 3.95 Bn |
| Jun 30, 2025 | 3.63 Bn |
| Mar 31, 2025 | 3.42 Bn |
| Dec 31, 2024 | 3.38 Bn |
| Sep 30, 2024 | 3.40 Bn |
| Jun 30, 2024 | 3.36 Bn |
| Mar 31, 2024 | 3.45 Bn |
| Dec 31, 2023 | 3.65 Bn |
| Sep 30, 2023 | 3.78 Bn |
| Jun 30, 2023 | 3.98 Bn |
| Mar 31, 2023 | 4.27 Bn |
| Dec 31, 2022 | 4.52 Bn |
| Sep 30, 2022 | 4.93 Bn |
| Jun 30, 2022 | 5.49 Bn |
| Mar 31, 2022 | 5.95 Bn |
| Dec 31, 2021 | 4.74 Bn |
| Sep 30, 2021 | 3.48 Bn |
| Jun 30, 2021 | 3.81 Bn |
| Mar 31, 2021 | 3.94 Bn |
| Dec 31, 2020 | 4.08 Bn |
| Sep 30, 2020 | 3.42 Bn |
| Jun 30, 2020 | 2.69 Bn |
| Mar 31, 2020 | 1.90 Bn |
| Dec 31, 2019 | 1.14 Bn |
| Sep 30, 2019 | 1.43 Bn |
| Jun 30, 2019 | 1.60 Bn |
| Mar 31, 2019 | 1.69 Bn |
| Dec 31, 2018 | 1.87 Bn |
| Sep 30, 2018 | 1.61 Bn |
| Jun 30, 2018 | 1.29 Bn |
| Mar 31, 2018 | 1.02 Bn |
| Dec 31, 2017 | 717.19 Mn |
| Sep 30, 2017 | 510.16 Mn |
| Jun 30, 2017 | 289.29 Mn |
| Mar 31, 2017 | 330.66 Mn |
| Dec 31, 2016 | 270.37 Mn |
| Sep 30, 2016 | 203.94 Mn |
| Jun 30, 2016 | 231.57 Mn |
| Mar 31, 2016 | 70.67 Mn |